GlassScriptPhysician profile
Debra Maude
NPI 1912280165
$1,228.63
in general payments reported to CMS, 2019-2025
24 companies · $99.99 in 2025
The $99.99 reported for 2025 was less than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15.00 · 2022: $47.14 · 2023: $428 · 2024: $638 · 2025: $99.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $729 · Education: $438.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $728.56 |
| Education | $437.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $254.94 | 2023-2025 | |
| Astellas Pharma US INC | $110.24 | 2024 | Padcev |
| Gilead Sciences, INC. | $102.76 | 2024 | Trodelvy |
| Lilly USA, LLC | $87.62 | 2023-2024 | Verzenio, Jaypirca, Retevmo |
| Eisai INC. | $87.61 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $62.14 | 2021-2022 | |
| Sobi, INC | $54.90 | 2023-2024 | |
| Taiho Oncology, INC. | $53.17 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $46.46 | 2023-2024 | Enhertu, Calquence |
| Stemline Therapeutics INC. | $42.44 | 2024 | Orserdu |
| Merck Sharp & Dohme LLC | $42.38 | 2023-2024 | Keytruda, Welireg |
| Glaxosmithkline, LLC. | $34.40 | 2023-2024 | Jemperli, Zejula |
| Pharmaessentia USA Corporation | $32.01 | 2023-2024 | Besremi |
| Emmaus Medical, INC. | $30.27 | 2023 | Endari |
| Novartis Pharmaceuticals Corporation | $29.06 | 2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $20.52 | 2024 | Tecvayli, Talvey |
| E.R. Squibb & Sons, L.L.C. | $18.99 | 2024 | Opdualag |
| Daiichi Sankyo INC. | $18.85 | 2023 | Injectafer |
| Takeda Pharmaceuticals U.S.A., INC. | $18.34 | 2024 | Fruzaqla |
| Mirati Therapeutics, INC. | $18.16 | 2023 | Krazati |
| Jazz Pharmaceuticals INC. | $17.98 | 2024 | |
| Pfizer INC. | $15.79 | 2023 | |
| Genzyme Corporation | $15.16 | 2024 | |
| Servier Pharmaceuticals LLC | $14.44 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Maude listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.